TickerFacts.

Immucell Corp (ICCC): Total Liabilities

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2015-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$15.48M
As of 2025-12-31
$15.26M
As of 2026-06-30
+2.2%
3-year compound annual growth
+5.1%
5-year compound annual growth
+14.7%
10-year compound annual growth
$18.82M2010-12-31: $1.47M2011-12-31: $1.97M2012-12-31: $1.84M2013-12-31: $1.56M2014-12-31: $1.79M2015-12-31: $3.93M2016-12-31: $4.98M2017-12-31: $10.70M2018-12-31: $10.99M2019-12-31: $9.70M2020-12-31: $12.08M2021-12-31: $11.89M2022-12-31: $14.48M2023-12-31: $18.82M2024-12-31: $17.58M2025-12-31: $15.48M$15.48M
2010-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$15.48M-12.0%2026-03-30, Balance as of period end
2024-12-31$17.58M-6.6%2026-03-30, Balance as of period end
2023-12-31$18.82M+29.9%2025-03-28, Balance as of period end
2022-12-31$14.48M+21.8%2024-04-01, Balance as of period end
2021-12-31$11.89M-1.6%2023-03-29, Balance as of period end
2020-12-31$12.08M+24.6%2022-03-30, Balance as of period end
2019-12-31$9.70M-11.7%2021-03-30, Balance as of period end
2018-12-31$10.99M+2.6%2020-03-27, Balance as of period end
2017-12-31$10.70M+115.2%2019-03-22, Balance as of period end
2016-12-31$4.98M+26.7%2018-03-29, Balance as of period end
2015-12-31$3.93Mn/c2017-03-30, Balance as of period end
2014-12-31$1.79M+14.6%2016-03-25, Balance as of period end
2013-12-31$1.56M-14.8%2015-03-26, Balance as of period end
2012-12-31$1.84M-6.9%2014-03-26, Balance as of period end
2011-12-31$1.97M+34.2%2013-03-28, Balance as of period end
2010-12-31$1.47Mn/a2012-03-27, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Immucell Corp (ICCC)2025-12-31$15.48M-12.0%
Alpha Teknova, Inc. (TKNO)2025-12-31$34.81M-4.3%
Intellia Therapeutics, Inc. (NTLA)2025-12-31$170.73M-46.5%
Aspira Women's Health Inc. (AWHL)2025-12-31$12.39M+53.8%
Anbio Biotechnology (NNNN)2025-12-31$87.8K-94.9%
Biomerica Inc (BMRA)2026-05-31$4.13M+124.4%
Insight Molecular Diagnostics Inc. (IMDX)2025-12-31$57.22M+20.8%
Volitionrx Ltd (VNRX)2025-12-31$42.49M+19.7%
Celldex Therapeutics, Inc. (CLDX)2025-12-31$55.82M+23.1%

Compare ICCC, TKNO, NTLA, AWHL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗